Team:Baskent Meds/Safety
From 2013.igem.org
(Prototype team page) |
|||
(21 intermediate revisions not shown) | |||
Line 1: | Line 1: | ||
- | |||
- | |||
<html> | <html> | ||
- | < | + | <head> |
- | <div id=" | + | |
- | + | <title>Baskent_Meds IGEMwiki</title> | |
+ | <!--menu bar script--> | ||
+ | <script type="text/javascript" src="http://code.jquery.com/jquery-latest.min.js"></script> | ||
+ | <script type="text/javascript"> | ||
+ | $(document).ready(function(){ | ||
+ | |||
+ | $("ul.subnav").parent().append("<span></span>"); //Only shows drop down trigger when js is enabled - Adds empty span tag after ul.subnav | ||
+ | |||
+ | $("ul.topnav li span").click(function() { //When trigger is clicked... | ||
+ | |||
+ | //Following events are applied to the subnav itself (moving subnav up and down) | ||
+ | $(this).parent().find("ul.subnav").slideDown('fast').show(); //Drop down the subnav on click | ||
+ | |||
+ | $(this).parent().hover(function() { | ||
+ | }, function(){ | ||
+ | $(this).parent().find("ul.subnav").slideUp('slow'); //When the mouse hovers out of the subnav, move it back up | ||
+ | }); | ||
+ | |||
+ | //Following events are applied to the trigger (Hover events for the trigger) | ||
+ | }).hover(function() { | ||
+ | $(this).addClass("subhover"); //On hover over, add class "subhover" | ||
+ | }, function(){ //On Hover Out | ||
+ | $(this).removeClass("subhover"); //On hover out, remove class "subhover" | ||
+ | }); | ||
+ | |||
+ | }); | ||
+ | /*menu bar script*/ | ||
+ | </script> | ||
+ | |||
+ | |||
+ | <style> | ||
+ | /*menubar css*/ | ||
+ | |||
+ | body | ||
+ | { | ||
+ | margin-left:20px; | ||
+ | margin-right:20px; | ||
+ | padding:0; | ||
+ | font:10px normal Arial, Helvetica, sans-serif; | ||
+ | background: #fff url("http://mail.baskent.edu.tr/mail/igem/scriptler/menubar/body_bg.gif") repeat-x; | ||
+ | background-color: #FFFFFF; | ||
+ | } | ||
+ | ul.topnav | ||
+ | { | ||
+ | padding:0 20px; | ||
+ | margin:0; | ||
+ | float:left; | ||
+ | width:934px; | ||
+ | background:#222; | ||
+ | font-size:1.2em; | ||
+ | background:url("https://static.igem.org/mediawiki/2012/1/1b/Topnav_bg.gif") repeat-x; | ||
+ | } | ||
+ | ul.topnav li | ||
+ | { | ||
+ | float:left; | ||
+ | list-style-type:none; | ||
+ | margin:0; | ||
+ | padding:0 15px 0 0; | ||
+ | position:relative; /*--Declare X and Y axis base--*/ | ||
+ | } | ||
+ | ul.topnav li a | ||
+ | { | ||
+ | padding:10px 5px; | ||
+ | color:#fff; | ||
+ | display:block; | ||
+ | text-decoration:none; | ||
+ | float:left; | ||
+ | } | ||
+ | ul.topnav li a:hover | ||
+ | { | ||
+ | background:url("https://static.igem.org/mediawiki/2012/f/f5/Topnav_hover.gif") no-repeat center top; | ||
+ | } | ||
+ | ul.topnav li span | ||
+ | { | ||
+ | /*--Drop down trigger styles--*/ | ||
+ | width:17px; | ||
+ | height:35px; | ||
+ | float:left; | ||
+ | background:url("https://static.igem.org/mediawiki/2012/4/45/Subnav_btn.gif") no-repeat center top; | ||
+ | } | ||
+ | ul.topnav li span.subhover | ||
+ | { | ||
+ | /*--Hover effect for trigger--*/ | ||
+ | background-position: | ||
+ | center bottom; | ||
+ | cursor: pointer; | ||
+ | } | ||
+ | ul.topnav li ul.subnav | ||
+ | { | ||
+ | list-style:none; | ||
+ | position:absolute; /*--Important - Keeps subnav from affecting main navigation flow--*/ | ||
+ | left:0; | ||
+ | top:35px; | ||
+ | background:#333; | ||
+ | margin:0; | ||
+ | padding:0; | ||
+ | display:none; | ||
+ | float:left; | ||
+ | width:170px; | ||
+ | -moz-border-radius-bottomleft:5px; | ||
+ | -moz-border-radius-bottomright:5px; | ||
+ | -webkit-border-bottom-left-radius:5px; | ||
+ | -webkit-border-bottom-right-radius:5px; | ||
+ | border:1px solid #111; | ||
+ | } | ||
+ | ul.topnav li ul.subnav li | ||
+ | { | ||
+ | margin:0; | ||
+ | padding:0; | ||
+ | border-top:1px solid #252525; /*--Creates bevel effect--*/ | ||
+ | border-bottom:1px solid #444; /*--Creates bevel effect--*/ | ||
+ | clear:both; | ||
+ | width:170px; | ||
+ | } | ||
+ | html ul.topnav li ul.subnav li a | ||
+ | { | ||
+ | float:left; | ||
+ | width:145px; | ||
+ | background:#333 url("https://static.igem.org/mediawiki/2012/4/4b/Dropdown_linkbg.gif") no-repeat 10px center; | ||
+ | padding-left:20px; | ||
+ | } | ||
+ | html ul.topnav li ul.subnav li a:hover | ||
+ | { | ||
+ | /*--Hover effect for subnav links--*/ | ||
+ | background:#222 url("https://static.igem.org/mediawiki/2012/4/4b/Dropdown_linkbg.gif") no-repeat 10px center; | ||
+ | } | ||
+ | /*menu bar css*/ | ||
+ | .style2 { | ||
+ | font-family: "Gill Sans MT", Helvetica; | ||
+ | font-size: 18px; | ||
+ | } | ||
+ | .style8 {font-size: 24px} | ||
+ | .style9 {font-size: 20px; } | ||
+ | .style10 {font-size: 18px; } | ||
+ | |||
+ | |||
+ | <!-- css ayar çekmece | ||
+ | #mediawiki { | ||
+ | display:none; | ||
+ | } | ||
+ | |||
+ | #global { | ||
+ | display: none | ||
+ | } | ||
+ | |||
+ | //mediawiki altbannerını ve üstteki kullanıcı panellerini kapatıyor | ||
+ | .noprint { | ||
+ | display: none | ||
+ | } | ||
+ | |||
+ | #search-controls.noprint { display: none } | ||
+ | |||
+ | /*.mediawiki { display: none }*/ | ||
+ | #p-logo { display: none } | ||
+ | .globalWrapper { display: none } | ||
+ | .top-section { display: none } | ||
+ | #footer-box { display: none } | ||
+ | .search-controls { display: none } | ||
+ | #catlinks { display: none } | ||
+ | #top { display: none } | ||
+ | --> | ||
+ | </style> | ||
+ | |||
+ | <meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1"></head> | ||
+ | <body> | ||
+ | |||
+ | <div id="ana" style="position:absolute; left:-24px; top:-100px; width:1000px; height:1100px; z-index:1; background-color: #FFFFFF; layer-background-color: #FFFFFF; border: 1px none #000000;"> | ||
+ | <div id="menubar" style="position:absolute; left:25px; top:16px; width:1000px; height:200px; z-index:100000"> | ||
+ | |||
+ | |||
+ | <!--menu bar basladi --> | ||
+ | <article> | ||
+ | |||
+ | <ul style="font-weight: bold;" class="topnav"> | ||
+ | <li><a href="/Team:Baskent_Meds" title="BaskentMeds main page">Home</a></li> | ||
+ | |||
+ | |||
+ | <li><a href="/Team:Baskent_Meds/Project" title="Our Project Abstract">Project</a> | ||
+ | <ul style="font-weight: bold;" class="subnav"> | ||
+ | <li><a href="/Team:Baskent_Meds/Description" title="Project Description">Description</a></li> | ||
+ | <li><a href="/Team:Baskent_Meds/Parts" title="Parts">Parts</a></li> | ||
+ | <li><a href="/Team:Baskent_Meds/Lpdetect" title="Project Description">Legionella detection</a></li> | ||
+ | <li><a href="/Team:Baskent_Meds/Notebook" title="Our Beloved Notebook!">Notebook</a></li> | ||
+ | </ul> | ||
+ | </li> | ||
+ | |||
+ | <li><a href="/Team:Baskent_Meds/Team" title="Shall we meet?">Team</a> | ||
+ | |||
+ | <ul class="subnav"> | ||
+ | <li><a href="/Team:Baskent_Meds/Team#fi" title="Our Instructors">Instructors</a></li> | ||
+ | <li><a href="/Team:Baskent_Meds/Team#adv" title="Our Adisor">Advisor</a></li> | ||
+ | <li><a href="/Team:Baskent_Meds/Team#us" title="Us">Student Members</a></li> | ||
+ | |||
+ | </ul> | ||
+ | |||
+ | <li><a style="font-weight: bold;" href="/Team:Baskent_Meds/Gallery" title="For Fun!">Human Practice</a></li> | ||
+ | |||
+ | |||
+ | |||
+ | <li><a style="font-weight: bold;" href ="/Team:Baskent_Meds/Attributions" title="Extras!">Extras</a> | ||
+ | |||
+ | <ul style="font-weight: bold;" class="subnav"> | ||
+ | |||
+ | <li><a href="/Team:Baskent_Meds/Safety" title="İs it safe">Safety</a></li> | ||
+ | <li><a href="/Team:Baskent_Meds/Attributions" title="Attributions">Attributions</a></li> | ||
+ | |||
+ | </ul> | ||
+ | </li> | ||
+ | </li> | ||
+ | |||
+ | </ul> | ||
+ | <br><br><br> | ||
+ | <!-- menubar bitti--> | ||
+ | |||
+ | <div id="sosyalkardesim" class="style2" style=" width:100px ;position: relative; left: 820px; top: -50px"><br> | ||
+ | |||
+ | <a style="background: transparent" href="https://www.facebook.com/igembaskentmeds2013"><img width="26px" src="https://static.igem.org/mediawiki/2013/e/ef/Fbsa.png"></img></a> | ||
+ | <a style="background: transparent" href="https://twitter.com/igembaskentmeds"><img width="26px" src="https://static.igem.org/mediawiki/2013/e/ee/Twiasd.png"></img></a> | ||
+ | <a style="background: url(lock_icon.gif) transparent;" href="http://www.youtube.com/user/igembaskentmeds2013"><img width="40px" src="https://static.igem.org/mediawiki/2013/c/cd/Yubusa.png"></img></a> | ||
</div> | </div> | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
</div> | </div> | ||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | |||
- | + | <br /> | |
+ | <br /> | ||
+ | <div id="la'book" class="style2" style="position:absolute; left:25px; top:165px; width:200px; height:274px; z-index:1; overflow: visible;"> | ||
+ | <div id="gecher" style="position:absolute; left:2px; top:0px; width:970px; height:468px; z-index:1"> | ||
+ | |||
+ | <p class="style8"><strong>Biosafety Part1</strong></p> | ||
+ | </br> | ||
+ | |||
+ | <p align="left"><strong>Risks to the safety and health of the members or other working in the lab?</strong></p> | ||
+ | <p>Although we use Legionella pneumophila genes, we work on microorganisms with biosafety risk leve1. In addition our experiments are performed inside a laminar flow cabinet to reduce the risk. We are always wearing lab coats, gloves and googles while working in the lab.</p></br> | ||
+ | |||
+ | <p align="left"><strong>Risks to the safety and health of the general public, if released by design or by accident?</strong></p> | ||
+ | <p>E.coli (risk level 1) are already present in our environment and also they have low pathogenicity, so bacteriae we experiment on would not cause additional risk if such an event occurs.</p></br> | ||
+ | |||
+ | <p align="left"><strong>Risks to environment, if released by design or by accident?</strong></p> | ||
+ | <p>E.coli (risk level 1) is already present in our environment as explained above. Our modifications to E.coli cells do not increase pathogenicity of cells. Because we do not transfer any genes encoding virulence factors or any proteins associated to pathogenicity of E.coli </p></br> | ||
+ | |||
+ | <p align="left"><strong>Risks to security though macilious misuse by individuals, groups or countries?</strong></p> | ||
+ | <p>Such a situation would not increase the risk level of the strains used.</p></br> | ||
+ | |||
+ | <p align="left"><strong>If your project moved from a small-scale lab study to become widely used as a commercial/industrial product, what new risks might arise? </strong></p> | ||
+ | <p>The knowledge we generate, is not expected to be harmfull for the environment or human health. Our methods are to detect Legionella pneumophilla, so we think our method won’t cause a risk for humans. On the other hand, our product in a plasmid vector, that is always possible to use it for different aims.</p></br> | ||
+ | |||
+ | <p align="left"><strong>Does your project include any design features to address safety risks?</strong></p> | ||
+ | <p>We cloned L.pneumophila’s autoinducer gene to E.coli and producer L.pneumophila mimicking E.coli. so we aim to observe the response our processed QS wsith by using the transformed E.coli producing Legionella autoinducers instead of the actual L.pneumophila cells.</p></br> | ||
+ | |||
+ | <p align="left"><strong>What safety have you received?</strong></p> | ||
+ | <p>We received biosafety course during phase 1 of the Medical School. In addition, we also received biosafety training before the experiments. In this context we learned chemical and biological hazardous material and using these substances during experiments | ||
+ | Unfortunately our institute does not have online biosafety guidelines. We use National Biosafety Guidelines. </p></br> | ||
+ | |||
+ | <p align="left"><strong>Does your institution have an institutional Biosafety Committee, or an equivalent group?</strong></p> | ||
+ | <p>We have our Başkent University Institutional Review Board and Ethics Committee evaluating the scientific and ethical legal and social issues of any project sumitted. This study was approved by this Committee(DA13/06) </p></br> | ||
+ | |||
+ | <p align="left"><strong>Does your country have national biosafety regulations or guidelines?</strong></p> | ||
+ | <p><a href="http://www.tbbdm.gov.tr/en/Home.aspx">http://www.tbbdm.gov.tr/en/Home.aspx</a></p></br> | ||
+ | |||
+ | <p align="left"><strong>According to the WHO Biosafety Manual, what is the BioSafety Level rating of your lab?</strong></p> | ||
+ | <p>Level2. Our laboratory’s BSL rating is above the risks caused by biomaterials we use. Also we run our experiments inside a laminar flow cabinet.</p></br> | ||
+ | |||
+ | <p class="style8"><strong>Biosafety Part2</strong></p> | ||
+ | </br> | ||
+ | |||
+ | <p align="left"><strong>Organism name and strain name or number</strong></p> | ||
+ | <p>Legionella pneumophila serogroup 1, strain Philadelphia</p></br> | ||
+ | |||
+ | <p align="left"><strong>If you are using this organism as a chassis, write "chassis". If you are using a genetic part from the organism, give the name of the part and a brief description of what it does and why you are | ||
+ | using it.</strong></p> | ||
+ | <p>Lqs gene cluster: This genetic part is used for developing a sensory system which recognizes Legionella pneumophila existence. This part is a segment of Legionella genomic DNA.</p></br> | ||
+ | |||
+ | <p align="left"><strong>How did you physically acquire the organism or part? | ||
+ | 5.</strong></p> | ||
+ | <p>Source plazmid (pNT-1) was donated by Prof. Dr. Hubert Hilbi.</p></br> | ||
+ | |||
+ | <p align="left"><strong>What potential safety/health risks to team members, other people at your institution, or the | ||
+ | general public could arise from your use of this organism/part?</strong></p> | ||
+ | <p>We use E. coli as a chassis. E. coli (risk level 1) is already present in our environment and also they have low pathogenicity, and our modifications to E.coli cells do not increase pathogenicity of cells, since we do not transfer any genes encoding proteins associated to pathogenicity of E. coli. </p></br> | ||
+ | |||
+ | <p align="left"><strong>What measures do you intend to take to ensure that your project is safe for team members, | ||
+ | other people at your institution, and the general public?</strong></p> | ||
+ | <p>Although we use Legionella pneumophila genes, we work on microorganisms with biosafety risk level 1. In addition, our experiments are performed inside a laminar flow cabinet to reduce the risk. We are always wearing lab coats, gloves and goggles while working in the lab.</p></br> | ||
+ | |||
+ | <p align="left"><strong>If you are using only a part from the organism, and you believe the part by itself is not | ||
+ | dangerous, explain why you believe it is not dangerous.</strong></p> | ||
+ | <p>There are no shown data about the pathogenicity of protein products of lqs gene locus.</p></br> | ||
+ | |||
+ | <p align="left"><strong>Why do you need to use this organism/part? Is there an organism/part from a less dangerous | ||
+ | Risk Group that would accomplish the same purpose?</strong></p> | ||
+ | <p>We aim to develop a system which is able to recognize Legionella existence at species level. In order to do that, we use quorum sensing mechanism, a communication system specific to species. We did not come across a less dangerous biological system which can recognize Legionella and react to it at species level.</p></br> | ||
+ | |||
+ | <p align="left"><strong>Is the organism/part listed under the Australia Group guidelines, or otherwise restricted for | ||
+ | transport? If so, how will your team ship this part to iGEM and the Jamborees?</strong></p> | ||
+ | <p>Although Legionella pneumophila is in the warning list, it states that biological materials, which are contaminated with virulence factors or directly organism istself, should be checked. We did not come across any information about organism's genetic material. Part shipment is done by standard methods.</p></br> | ||
+ | |||
+ | <p align="left"><strong>Please describe the BioSafety Level of the lab in which the team works, or description of | ||
+ | safety features of lab (Refer to Basic Safety form, question 8. d.). If you are using organisms with | ||
+ | a BSL level greater than you lab, please explain any additional safety precautions you are taking.</strong></p> | ||
+ | <p>Our laboratory's BSL rating is above the risks caused by biomaterials we use. Also we run our experiments inside a laminar flow cabinet.</p></br> | ||
+ | |||
+ | </br> | ||
+ | <p class="style8"><strong>Safety forms were approved on October 2nd, 2013 by the iGEM Safety Committee.</strong></p> | ||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | <div id="Our Proudly Sponsors" class="style2" align="center"> | ||
+ | </br> | ||
+ | </br> | ||
+ | </br> | ||
+ | <p><strong>Our Sponsors</strong></p> | ||
+ | <a href="http://www.baskent.edu.tr" title="Başkent Üniversitesi"><img src="https://static.igem.org/mediawiki/2013/3/30/Baskentlogo.gif" width="100" height="90" ></a><a href = "http://www.tubitak.gov.tr" title="TÜBİTAK"><img src="https://static.igem.org/mediawiki/2013/b/bf/Tubitaklogo.jpg" width="100" height="90"></a><a href = "http://www.home.agilent.com/agilent/home.jspx?lc=eng&cc=TR" title="Agilent Türkiye"><img src="https://static.igem.org/mediawiki/2013/c/c3/Aglientsmszw.png" width="100" height="90"></a> | ||
+ | </br> | ||
+ | </br> | ||
+ | </br></div> | ||
+ | </div> |
Latest revision as of 18:29, 4 October 2013
Biosafety Part1
Risks to the safety and health of the members or other working in the lab?
Although we use Legionella pneumophila genes, we work on microorganisms with biosafety risk leve1. In addition our experiments are performed inside a laminar flow cabinet to reduce the risk. We are always wearing lab coats, gloves and googles while working in the lab.
Risks to the safety and health of the general public, if released by design or by accident?
E.coli (risk level 1) are already present in our environment and also they have low pathogenicity, so bacteriae we experiment on would not cause additional risk if such an event occurs.
Risks to environment, if released by design or by accident?
E.coli (risk level 1) is already present in our environment as explained above. Our modifications to E.coli cells do not increase pathogenicity of cells. Because we do not transfer any genes encoding virulence factors or any proteins associated to pathogenicity of E.coli
Risks to security though macilious misuse by individuals, groups or countries?
Such a situation would not increase the risk level of the strains used.
If your project moved from a small-scale lab study to become widely used as a commercial/industrial product, what new risks might arise?
The knowledge we generate, is not expected to be harmfull for the environment or human health. Our methods are to detect Legionella pneumophilla, so we think our method won’t cause a risk for humans. On the other hand, our product in a plasmid vector, that is always possible to use it for different aims.
Does your project include any design features to address safety risks?
We cloned L.pneumophila’s autoinducer gene to E.coli and producer L.pneumophila mimicking E.coli. so we aim to observe the response our processed QS wsith by using the transformed E.coli producing Legionella autoinducers instead of the actual L.pneumophila cells.
What safety have you received?
We received biosafety course during phase 1 of the Medical School. In addition, we also received biosafety training before the experiments. In this context we learned chemical and biological hazardous material and using these substances during experiments Unfortunately our institute does not have online biosafety guidelines. We use National Biosafety Guidelines.
Does your institution have an institutional Biosafety Committee, or an equivalent group?
We have our Başkent University Institutional Review Board and Ethics Committee evaluating the scientific and ethical legal and social issues of any project sumitted. This study was approved by this Committee(DA13/06)
Does your country have national biosafety regulations or guidelines?
http://www.tbbdm.gov.tr/en/Home.aspx
According to the WHO Biosafety Manual, what is the BioSafety Level rating of your lab?
Level2. Our laboratory’s BSL rating is above the risks caused by biomaterials we use. Also we run our experiments inside a laminar flow cabinet.
Biosafety Part2
Organism name and strain name or number
Legionella pneumophila serogroup 1, strain Philadelphia
If you are using this organism as a chassis, write "chassis". If you are using a genetic part from the organism, give the name of the part and a brief description of what it does and why you are using it.
Lqs gene cluster: This genetic part is used for developing a sensory system which recognizes Legionella pneumophila existence. This part is a segment of Legionella genomic DNA.
How did you physically acquire the organism or part? 5.
Source plazmid (pNT-1) was donated by Prof. Dr. Hubert Hilbi.
What potential safety/health risks to team members, other people at your institution, or the general public could arise from your use of this organism/part?
We use E. coli as a chassis. E. coli (risk level 1) is already present in our environment and also they have low pathogenicity, and our modifications to E.coli cells do not increase pathogenicity of cells, since we do not transfer any genes encoding proteins associated to pathogenicity of E. coli.
What measures do you intend to take to ensure that your project is safe for team members, other people at your institution, and the general public?
Although we use Legionella pneumophila genes, we work on microorganisms with biosafety risk level 1. In addition, our experiments are performed inside a laminar flow cabinet to reduce the risk. We are always wearing lab coats, gloves and goggles while working in the lab.
If you are using only a part from the organism, and you believe the part by itself is not dangerous, explain why you believe it is not dangerous.
There are no shown data about the pathogenicity of protein products of lqs gene locus.
Why do you need to use this organism/part? Is there an organism/part from a less dangerous Risk Group that would accomplish the same purpose?
We aim to develop a system which is able to recognize Legionella existence at species level. In order to do that, we use quorum sensing mechanism, a communication system specific to species. We did not come across a less dangerous biological system which can recognize Legionella and react to it at species level.
Is the organism/part listed under the Australia Group guidelines, or otherwise restricted for transport? If so, how will your team ship this part to iGEM and the Jamborees?
Although Legionella pneumophila is in the warning list, it states that biological materials, which are contaminated with virulence factors or directly organism istself, should be checked. We did not come across any information about organism's genetic material. Part shipment is done by standard methods.
Please describe the BioSafety Level of the lab in which the team works, or description of safety features of lab (Refer to Basic Safety form, question 8. d.). If you are using organisms with a BSL level greater than you lab, please explain any additional safety precautions you are taking.
Our laboratory's BSL rating is above the risks caused by biomaterials we use. Also we run our experiments inside a laminar flow cabinet.
Safety forms were approved on October 2nd, 2013 by the iGEM Safety Committee.